High-throughput DNA sequencing enables detection of copy number variations (CNVs) 2 on the genome-wide scale with finer resolution compared to array-based methods, but 3 suffers from biases and artifacts that lead to false discoveries and low sensitivity. We 4 describe CODEX2, a statistical framework for full-spectrum CNV profiling that is sensitive 5 for variants with both common and rare population frequencies and that is applicable to 6 study designs with and without negative control samples. We demonstrate and evaluate 7 CODEX2 on whole-exome and targeted sequencing data, where biases are the most 8 prominent. CODEX2 outperforms existing methods and, in particular, significantly 9 improves sensitivity for common CNVs. 10 11
based on the simple intuition that regions with copy number gain should have increased 48 read coverage, and regions with copy number loss should have decreased read coverage. 49
However, read coverage depends not just on copy number but also on many other factors, 50 such as GC content [7] , mappability [8] , and other local sequence characteristics [9] . 51 Therefore, read coverage tends to fluctuate even when there is no CNV, and is especially 52 variable in WES and targeted sequencing data due to the biases and artifacts introduced 53 during the targeting and amplification steps [10] [11] [12] . 54
Many methods are available for CNV detection in high throughput sequencing data 55 [10] [11] [12] [13] [14] [15] [16] . Despite much progress however [17], significant challenges still remain. 56 Independent benchmark results from multiple studies [10, 12, 14, 18] show that existing 57 methods suffer from low precision and recall rates, especially for the detection of common 58 germline CNV signals. These results are not unexpected, since in WES and targeted 59 sequencing data, and also to an extent in WGS data, the technical background bias for 60 each genomic target varies across samples, leading to false positives and negatives if 61 not properly removed. To remove this technical background, recent methods have relied 62 on low-dimensional linear factor models to capture the background bias [10, 11] , which 63 tend to control for false positives. However, these low-dimensional linear factor models 64 tend to remove common CNVs that correlate with the estimated factors. CLAMMS [19] is 65 developed to recover common CNV signals by WES but is not suitable for cancer samples, 66
where recurrent somatic copy number changes are prominent. In this paper, we 67 demonstrate that this issue also affects the detection of somatic CNVs in cancer genomes, 68
as CNVs that are recurrent across multiple cancer samples can be accidentally removed 69 in the normalization step. Due to these limitations, current genetic studies using WES and 70 targeted sequencing data have focused mostly on single nucleotide variations and, at 71 best, rare CNVs [20] [21] [22] .
with matched microarrays and experimental validation [23-25] to assess performance. 80
Our results demonstrate that CODEX2 significantly improves both sensitivity and 81 specificity over existing methods, especially for common CNVs. Next, we applied 82 CODEX2 to targeted sequencing data of melanoma cancer cell lines, patient derived 83 xenografts (PDX) and tumor biopsies, and successfully identified recurrent CNVs whose 84 frequencies are highly concordant with those obtained from a separate cohort studied by 85 the Cancer Genome Atlas (TCGA) [1] . Finally, we performed extensive simulations to 86 benchmark existing methods and to explore how key variables, such as population 87 frequency and CNV length, influence performance. CODEX2 is compiled as an open-88 source R-package available at https://github.com/yuchaojiang/CODEX2. 89 90 Results 91
Methods overview 92
Figure 1 illustrates the two experimental designs for which CODEX2 can be applied: (i) 93 case-control design with a group of negative control samples, where the goal is to detect 94 CNVs disproportionately present in the 'cases' versus the 'controls' ( Figure 1A) ; and (ii) 95 detection of all CNVs present in all samples design, such as in ExAC ( Figure 1B) . The 96 key innovation in CODEX2 is the way that it harnesses negative control genome regions 97 and/or negative control samples in its genome-wide latent factor model for sample-and 98 position-specific background correction. The negative control genome regions defined by 99 CODEX2 are regions that do not harbor common CNVs, but that are still allowed to harbor 100 rare CNVs, and can be constructed from existing studies or learned from data. 101 is especially severe for CNV A, which is correlated with the one-dimensional background 113 batch. For CODEX2, in scenarios for which negative controls are available, only the 114 negative controls are used to fit the latent factor model, which is then used to predict the 115 background bias of the rest of the samples. In scenarios for which negative control 116 samples are not available but negative control regions are identified, the latent factor 117 model is fitted only using the negative control regions, and then used to "fill in" the 118 background bias for the rest of the regions. In this way, we avoid the contamination of the 119 background estimates by the CNV signal, thus attaining better separation of signal from 120 noise, as can be seen from the histograms of the normalized -scores. More details are 121 given in Methods. 122 CODEX2 estimates a separate background factor for each genomic target/region 123 in each sample, which can then be used to normalize the observed coverage and detect 124 CNV regions using the recursive Poisson-likelihood segmentation algorithm in Jiang et al. 125
[12]. 126 127
Analysis of WES and WGS data from the 1000 Genomes Project 128
We first evaluated CODEX2 by reanalyzing a publicly available WES data set from the 129 7 To assess performance of CODEX2 and to benchmark against existing methods, 136
we used WGS CNV calls from phase 3 release [2], as well as the experimentally validated 137 CNVs from three previous microarray studies [23-25] as gold standards. Specifically, we 138 adopted stringent quality control procedures (i.e., the reported CNV must overlap with at 139 least two and at most 20 exons, have less than 5% NA rate across all samples, and have 140 at most three copy number states). These 'gold-standard' CNVs, shown in Supplementary 141 Table  145 3. Figure 3 and Supplementary Table 4 show the precision and recall rates across the 146 four benchmarked methods, using the CNVs validated by each of the four studies as 147 ground truth. The grey lines are the contours of the -measure, defined as the harmonic 148 mean of precision and recall. XHMM, which is designed for detection of rare CNVs, lacks 149 sensitivity to common CNVs, so does EXCAVATOR. CODEX detects proportionately 150 more common CNVs but still lacks sensitivity. CLAMMS retains high precision rates 151 overall but suffers from low sensitivity. CODEX2 achieves a recall rate of 92.8%, 60.7%, 152 79.2%, and 66.2% in the four validation sets, respectively, while simultaneously making 153 substantial improvements to specificity. CODEX2 does not dominate in the phase 3 WGS 154 validation set, potentially due to the false calls in the set (Supplementary Figure 1) . Overall, 155 CODEX2 achieves good performance for both common and rare CNVs, with significant 156 improvement in precision and recall for common CNV detection. 157
We further demonstrate CODEX2 on a WGS dataset of 108 individuals from the 158 1000 Genomes Project ( Supplementary Table 1 ), out of which there are three family trios 159 (Supplementary Table 5 ). We applied CODEX2 and CNVnator [26] to profile germline 160
CNVs and assessed performance using the Mendelian concordance rates between 161 children and their parents as metric. CODEX2 and CNVnator on average returned 1011 162 and 118 CNVs per individual, respectively (see Supplementary Table 6 for calling results). would have an inflated cross-sample concordance close to one. Therefore, we assess 170 call accuracy using the ratio of child-parent concordance over the concordance between 171 the two unrelated parents. This measure of concordance enrichment more accurately 172 reflect call set quality. 173 174
Analysis of targeted sequencing data of melanoma cases and controls 175
We further applied CODEX2 to a cohort study of melanoma from Garman et al. We applied CODEX2 to this data set and compare to CODEX. The number of 184
Poisson latent factors in the background model is determined by the Bayesian information 185 criterion (BIC) for both programs. The use of negative controls in estimating the 186 background model allowed CODEX2 to be more robust to model tuning. For CODEX2, 187 the number of latent factors had minimal effect on normalization and more generally on 188 CNV detection, as only the normal samples were used to estimate the bias coefficient for 189 each exon ( Supplementary Table 7 ). In comparison, for CODEX, the number of CNV 190 events decreased as the number of latent factors increased ( Supplementary Table 7 ). 191
Since the 108 genes are sparsely scattered across the genome, segmentation is 192 performed within each gene separately. Furthermore, due to clonal heterogeneity and 193 normal cell contamination, copy numbers may not be integers, and are assumed to be 194 continuous and fractional to represent attenuated mean estimates of the genome 195 mixtures. We categorize a CNA event to be high gain, gain, diploid, one-copy deletion, 196 and two-copy deletion, if the profiled copy number is above 3.3, between 2.3 and 3.3, 9 between 1.7 and 2.3, between 0.7 and 1.7, and below 0.7, respectively. Figure 4 shows 198 the heatmaps of the segmentation results by CODEX and CODEX2. Each row 199 corresponds to a sample, with the first 16 samples towards the bottom corresponding to 200 the normal controls; each column corresponds to a target in the gene panel. In melanoma, 201 somatic deletions of tumor suppressors (e.g., PTEN) and duplications of oncogenes (e.g., 202 BRAF) are known to have high incidence rates [1] . From visual inspection of the heatmaps 203
in Figure 4 , we see that CODEX2 successfully retains these expected recurrent deletions 204 and duplications, while CODEX, which does not make use of the negative control samples 205
in fitting the background model, misinterprets the recurrent signals as a background latent 206 factor. 207
To rigorously evaluate CODEX2's accuracy on this data, we compared the 208 frequencies of the profiled gains and losses, that is, the proportion of samples in which a 209 call is made, with frequencies from an independent melanoma patient cohort in TCGA [1]. 210
Specifically, for each gene target, we plotted in Figure 5 the proportion of samples 211 carrying a deletion (or duplication) in TCGA, versus this corresponding proportion in our 212 current data set. CODEX2 achieves much higher concordance with TCGA results, with 213 overall correlation across genes reaching 0.842 for deletions and 0.853 for gains, as 214 compared to CODEX (correlation = 0.52 for deletions and 0.049 for gains). CODEX2 215 detects in these cell line samples a higher frequency of BRAF amplification and CDKN2A 216 loss, as compared to the frozen-tissue derived TCGA results, which is not surprising due 217 to the relative in vitro growth advantage of cells carrying these mutations. Based on the 218 results by CODEX2, Garman et al. [27] further separated the cohort based on cancer 219 subtypes and clinicopathological characteristics (responses to targeted and/or 220 immunotherapy) and investigated the differences in mutational profiles between groups. 221
The accurate profiling of CNVs in this data set enables unbiased downstream analysis. 222 223
Performance assessment via spike-in studies 224
To understand how variables such as CNV length and population frequency affected the 225 sensitivity of CODEX, CODEX2, and methods based on singular value decomposition 226
(SVD, such as XHMM and CoNIFER), we conducted in silico spike-in studies. We started 227 with the exon read depth data from chromosomes 16 to 22 in the 90 samples we analyzed 10 from the 1000 Genomes Project, and applied filtering to remove putative existing CNVs. 229
We then added, to the background count matrix under the null, heterozygous CNV signals 230 of varying length, frequency, and degree of correlation with the first latent factor in the 231 background model. See details of simulation setup in Methods. 232
As an illustration, Figure 6 shows a small subset of the CNV regions in the spike-233 in data with the ground truth, the post-normalization heatmap, and the CNV assignments 234 across multiple methods, with the "null" regions containing no CNVs removed for easier 235 visualization. The histograms in Figure 6 show the distribution of the normalized -scores, 236
with exons that harbor CNVs in red and exons within diploid regions in grey. We see that 237 We systematically compare the performance of CODEX2 against existing methods 251 by spiking in deletions and duplications of length 5, 10, 20, and 40 exons with population 252 frequency ∈ {5%, 10%, … ,95%}, repeating each simulation run 20 times. The precision 253 and recall rates achieved by each method are shown in Figure 7 , Supplementary Table  254 8, and Supplementary Table 9 . Figure 7 shows how two variables, population frequency 255 and degree of correlation with batch effect, impact the accuracy of methods. The results 256
show that CODEX and SVD-based methods are sensitive to both variables, while 257 CODEX2 maintains high accuracy across all frequencies and all degrees of correlation. 258 CODEX2 has nearly perfect performance, whereas CODEX and SVD-based methods 259 suffer from low sensitivity and specificity, especially for common CNVs with frequencies 260 around 50%. We also investigated the effect of CNV length on performance and 261 demonstrated that CODEX and SVD-based methods have lower sensitivity and specificity 262 for longer CNVs, as compared to CODEX2 ( Supplementary Figure 6 , Supplementary 263 Table 8 ). 264
We further studied the relationship between CNV carrier status and batch effects- We also performed additional simulations where we spiked in CNV signals to 279 mimic those that are observed in genetically heterogeneous mixtures, such as cancer. 280
Specifically, in each sample we added CNV signals as a mixture of % cells with copy 281 number (sampled from a Gaussian distribution with mean 1 for heterozygous deletion) 282
and (1 − )% cells with copy number 2. If the copy number change event is clonal in the 283 cancer sample, is referred to as purity in cancer genomics study, which is the proportion 284 of cancer cells out of the entire cell population; if the copy number change is subclonal, 285 is the cancer cell frequency for the CNV event. Our results show that CODEX2 is able to 286 recover CNV signals with decent sensitivity and specificity for as low as 30% 287
( Supplementary Table 10 sample-specific backgrounds that can be more effective. CLAMMS, however, cannot be 304 applied to WGS data or cancer samples and SVD is designed for capturing linear biases 305 in continuous-valued observations. GC content has been shown to have a sample-306 specific, non-linear bias in sequencing data. Furthermore, read counts are not fit well by 307
Gaussian models, even after transformation, due to their fluctuation over a very wide 308 range. Our previous work, CODEX [12] , adopts a Poisson latent factor model for count-309 based sequencing data and estimates a sample-specific background for each genomic 310 position that incorporates nonlinear biases due to GC content, target-specific capture and 311 amplification efficiency, and low-dimensional latent systemic artifacts. 312
We will start by giving an overview of the SVD-based methods by CoNIFER [10] 313 and XHMM [11] and the Poisson latent factor model by CODEX [12] . We will discuss the 314 limitations of existing models and the reason why they lack sensitivity for common CNVs. 315
We will then describe the model for CODEX2, leaving algorithmic details to the 316
Supplements. 317
Denote as a × matrix of raw read depth, where corresponds to the read depth 320 We denote * as a set of indices of the exons that harbor highly recurrent CNVs, the 388 compliment of which are the indices of exons within the negative control regions. The set 389 * can be obtained based on prior knowledge (e.g., common deletions in tumor 390 suppressors), from existing database (e.g., the Database of Genomic Variants), or 391 empirically from a first-pass CODEX run. That is, if an exon lies within a common CNV 392 region, CODEX will return a high standard deviation of the normalized -scores across all 393 samples for this exon - Supplementary Figure 5 shows that for a common CNV, the 394 estimated null will be biased towards the alternative, especially when the incidence rate 395
is high. Figure 1B shows an example on identifying germline CNVs from a population of 396 samples (e.g., healthy individuals from the 1000 Genomes Project). For step 1 in 397
Supplementary Algorithm 2, we no longer have a set of controls samples to directly 398 estimate the exon-specific parameters. We propose an expectation-maximization (EM) 399 algorithm embedded in our iterative parameter estimation procedure, where the missing 400 data is the carrier status of the samples. Specifically, for each exon ∈ * , 401 * ~Poisson( * ), 402 log( * ) = log( ) + log( ( * )) + log( * ) + ∑ * ℎ =1 + * , 403
where 404 * = { * withprobability * , 0withprobability1 − * . 405 * is the incident rate for the CNV that span exon * , and * is the deviation from the null 406 on the log scale, which can be either pre-fixed (e.g., log(1 2 ⁄ ) for heterozygous deletion) 407 or estimated by CODEX2. For simplicity, here we show the case where there is only one 16 type of CNV event within the carriers. This can be easily extended to multiple subgroups 409 with a model selection metric, which is enabled in the CODEX2 package. , ( ), and 410 can be using negative control regions shown in Supplementary Algorithm 3 step 1 and 411 * = { 1ifsample hasCNVspanningexon * , 0otherwise. 414
Refer to Supplementary Algorithm 3 for implementation details. 415 CODEX2 offers the choice of Akaike information criterion (AIC), Bayesian 416 information criterion (BIC), and variance reduction to determine the optimal number of 417 latent factors. In CODEX and SVD-based methods (XHMM and CoNIFER), the number 418 of latent factors is a critical model tuning parameter that affects normalization and 419 segmentation results. It is often not clear whether to use the AIC, BIC, or simple visual 420 examination of the scree plot, and this arbitrariness plagues all methods that rely on SVD, 421 PCA, or factor models. By using negative controls to guide the estimation of the 422 background model, CODEX2 is less sensitive to the number of latent factors 423
( Supplementary Table 7 ), thus giving results that are easier to reproduce. 424 
Simulation setup 433
We start with the exonic read depth data of chromosomes 16 to 22 from the 90 samples 434 we analyzed from the 1000 Genomes Project, and apply filtering to remove putative 435 existing CNVs. Specifically, the filtering step removes all exons that: (i) are called to 436 harbor CNV events by XHMM, EXCAVATOR, CODEX, or CODEX2, (ii) overlap with 437 duplication and deletion reported in the Database of Genomic Variants, (iii) don't pass 438 quality control procedure by CODEX (median coverage between 40 and 4000, length between 30 and 2000 base pairs, mappability less than 0.95, GC content between 30% 440 and 70%), (iv) have standard deviation of normalized z-scores across samples above 0.3, 441 or maximum of normalized z-scores above 0.8, or minimum normalized z-scores below -442 0.8 across all samples. This way we are left with 4035 'null' exons that are CNV-free 443 across 90 samples. Treating this filtered count matrix as background, we fit the 444 background model of CODEX, with the estimated parameters as ground truth. The 445 optimal number of latent factors is 3 by AIC, BIC and variance reduction (Supplementary 446 Figure 4 ) and is kept the same for subsequent analysis for CODEX2, CODEX, and SVD-447 based method. We then add, to this background count matrix, heterozygous CNV signals 448 of varying length, frequency, and degree of correlation with the first latent factor in the 449 background model. In more detail, we spike in heterozygous deletions, of varying lengths 450 and population frequencies, by reducing the raw depth of coverage for exons spanned by 451 the CNV from to × 2 ⁄ , where is sampled from a normal distribution with mean 1 452 and standard deviation 0.1. Note that heterozygous deletions with frequency in the 453 population have exactly the same detection accuracy as duplications with frequency 1 − 454 , since all copy number events are defined in reference to a population average. To 455 confirm, we also spike in copy number gains with varying population frequencies where 456 is sampled from a Gaussian distribution with mean 3. To assess performance in cancer 457 genomics setting where the samples are heterogeneous, we further carry out spike-in 458 studies where CNV signals are added as a mixture, with % tumor cells having copy 459 number and (1 − )% normal cells having copy number 2. 460 461
Discussion and conclusions 462
A limitation shared by all existing CNV detection methods, highlighted by multiple 463 independent benchmarking studies, is the lack of sensitivity for common variants. 464
Similarly, in our experience applying CODEX [12] to WES and targeted sequencing of 465 tumor samples, we easily detect sporadic aberrations but miss highly recurrent 466 aberrations. To meet the widespread demand for improved CNV detection, we develop 467 in this paper a new method, CODEX2, to remove technical noise and improve CNV signal-468
to-noise ratio for all sequencing platforms including WES and targeted sequencing. sensitivity for common variants, thus allowing full-spectrum CNV detection. CODEX2 can 471 be applied in either the setting of a case-control analysis in which the goal is to detect 472
CNVs that are enriched in the case samples, or when the goal is simply to profile all CNVs. 473
We have benchmarked CODEX2 extensively against existing methods. In the first 474 evaluation, we reanalyzed WES data of the HapMap samples from the 1000 Genomes 475
Project, for which a set of experimentally validated CNV calls from microarrays and other 476 sources could be used to assess performance. Our results demonstrate that CODEX2 477 has markedly improved sensitivity and specificity over existing methods. The 478 improvement for calling of common variants is the most substantial, from 40% recall rate 479 to >80% recall rate, in two out of the three validation sets used, while simultaneously 480 improving precision from 60% to 90%. In the second evaluation, we applied CODEX2 to 481 targeted sequencing data of melanoma cell lines, PDX, and tumor samples, in which 482 CODEX2 detects CNVs with recurrence rates that are highly concordant with those 483 obtained from TCGA. Finally, we performed extensive simulations benchmarking existing 484 methods and elucidated how key variables, such as population frequency, influence 485 detection sensitivity. Together, these results establish the improved accuracy of CODEX2 486 over existing state-of-the-art approaches, and the utility of the software under varying 487 study designs. 488
Under a different context, for the detection of differential expression in RNA 489 sequencing data, Risso et al. [29] proposed the normalization method "removing 490 unwanted variation" (RUV) which is based on a factor model that relies on sets of control 491 genes or samples for estimation. CODEX2 resembles RUV but has distinguishing 492 features. First, RUV is designed to be used in a case-control setting. CODEX2 can be 493 
Figure legends

